HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,075,139 | +6.1% | 28,145 | +0.2% | 0.02% | +6.7% |
| Q2 2023 | $1,013,242 | -5.4% | 28,091 | +0.1% | 0.02% | -11.8% |
| Q1 2023 | $1,071,574 | -59.1% | 28,059 | -39.0% | 0.02% | -59.5% |
| Q4 2022 | $2,616,945 | +53.8% | 45,992 | +6.9% | 0.04% | +40.0% |
| Q3 2022 | $1,701,000 | -0.5% | 43,028 | +10.7% | 0.03% | +3.4% |
| Q2 2022 | $1,710,000 | +11.0% | 38,863 | +0.6% | 0.03% | +31.8% |
| Q1 2022 | $1,541,000 | +0.6% | 38,647 | +1.4% | 0.02% | +10.0% |
| Q4 2021 | $1,532,000 | -12.0% | 38,100 | -11.0% | 0.02% | -20.0% |
| Q3 2021 | $1,741,000 | +16.2% | 42,786 | +29.7% | 0.02% | +19.0% |
| Q2 2021 | $1,498,000 | +8.9% | 32,982 | -0.1% | 0.02% | 0.0% |
| Q1 2021 | $1,376,000 | +40.7% | 33,000 | +44.2% | 0.02% | +31.2% |
| Q4 2020 | $978,000 | +65.2% | 22,891 | +1.7% | 0.02% | +45.5% |
| Q3 2020 | $592,000 | +1.0% | 22,506 | +3.0% | 0.01% | -8.3% |
| Q2 2020 | $586,000 | +860.7% | 21,860 | +541.2% | 0.01% | +1100.0% |
| Q1 2020 | $61,000 | – | 3,409 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |